



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 13 Feb 2018 (#4)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- **Strengthen Your Application With Preliminary Research** Your preliminary research may be the difference between your application's scoring within or short of paylines. For R01s, the thoroughness of your preliminary research can be just as important for impressing peer reviewers as the Specific Aims it supports.
- **No Clinical Trial-Related Materials Allowed in Appendix** Unless otherwise noted in the funding opportunity announcement to which you are applying, you can no longer include clinical trial-related materials in the Appendix of your grant application.
- **Interim Final Rule: Six-Month Delay, For Now** The latest revision to the Federal Policy for the Protection of Human Subjects ("Common Rule") will kick in later to allow more time for organizations to implement the requirements and for stakeholders to comment about whether there is need for an additional delay. In practice, NIH has already incorporated many of the policy's human subjects protections into NIH-level requirements.
- **When and How To Contact a Program Officer** Before you email or leave a voicemail for your program officer, ask yourself: Am I certain he or she is the person I need to answer my question or resolve my issue?
- **What is a select agent or toxin?** Select agent or toxin means unless otherwise specified, any of the biological agents or toxins listed in [42 CFR 73.3 and 73.4](#). These biological agents and toxins have the potential to pose a severe threat to both human and animal health, plant health, or animal and plant products. [42 C.F.R. Part 73: Public Health](#)

1. National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Implementation Cooperative Agreement (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-18-633](#)

Type: U01

Application Due Date: May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019; September 13, 2019; January 13, 2020; May 13, 2020; September 14, 2020; January 13, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<https://www.niaid.nih.gov/research/role>). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

2. Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-18-630](#)

Type: R01

Application Due Date: April 10, 2018; December 7, 2018; March 7, 2019; December 7, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an **extended project period of 6 or 7 years**. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period of 6 or 7 years.

3. Dementia Care and Caregiver Support Interventions (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink:

Type: R01

Application Due Date: April 10, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overarching purpose of this FOA is to help to lay the groundwork for pragmatic trials and real-world implementation of Alzheimer's disease (AD) and AD-related dementias (ADRD) care and caregiving interventions by supporting early-stage (Stage I, II, III of the NIH Stage Model) behavioral intervention development clinical trials aimed at adapting/modifying interventions for the real world, examining the principles underlying these interventions, developing methods to ensure real-world fidelity of delivery, and developing training procedures for the people in the community who will be delivering the interventions. AD/ADRD care and caregiver support intervention research can be for implementation in the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. These interventions may target behavioral, psychological, interpersonal, social, or institutional processes and may be designed for use at the individual, family, dyad, group, community, or health systems level. Applications may propose intervention research for any stage of AD/ADRD. Applications addressing care needs and challenges for individuals from diverse racial, ethnic, and socioeconomic backgrounds are strongly encouraged. Applicants should specify the disease stage(s), the setting/context, and the population being studied. Applications that involve interdisciplinary expertise and translational expertise (e.g., basic science expertise as appropriate regarding questions about mechanisms, implementation expertise as appropriate when designing real-world friendly interventions) are strongly encouraged. Applications proposing to create, modify, and test AD/ADRD care and caregiver support interventions are encouraged, as appropriate, to incorporate the NIH Science of Behavior Change (SOBC) experimental medicine approach.

Budget: NIA intends to commit \$3,000,000 in FY 2018 to fund 5-8 awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. No more than \$350,000 in direct costs may be requested in any single year. Application budgets need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Limited Competition for the Continuation of the Clinical Centers for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-DK-17-511\)](#)

Type: U01

Application Due Date: April 26, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Limited Competition Funding Opportunity Announcement (FOA) invites applications from the Program Directors/Principal Investigators of the six current Clinical Centers (CCs) for The Environmental Determinants of Diabetes in the Young (TEDDY) study, an ongoing epidemiological study of Type 1 Diabetes (T1D) etiology. The TEDDY study involves the rigorous investigation of TEDDY subjects, collecting data and samples, for the identification of infectious agents, dietary factors, or other environmental factors associated with onset of T1D and/or T1D associated autoimmune markers. The six current CCs have been involved in study design and data and biosample acquisition since the inception of the TEDDY consortium. The CCs have recruited participants and followed the subjects over the past 15 years. In addition, the CCs have established effective and proficient collaborations with other components of TEDDY to carry out the studies to meet the objectives of this program.

Budget: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to commit \$5,500,000 to fund 6 awards in FY 2018. The number of awards is contingent upon availability of funds and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$1,100,000 direct costs per year. The maximum project period is 5 years.

5. Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-ES-18-004\)](#)

Type: R35

Application Due Date: June 20, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute of Environmental Health Sciences (NIEHS) Revolutionizing Innovative, Visionary Environmental health Research (RIVER) program seeks to provide support for the majority of the independent research program for outstanding investigators in the Environmental Health Sciences, giving them intellectual and administrative freedom, as well as sustained support to pursue their research in novel directions in order to achieve greater impacts. The program seeks to identify individuals, regardless of career stage, with a potential for continued innovative and impactful research and combine their existing investigator-initiated research into a single award with a duration of up to 8 years and direct costs of \$600,000 and potentially up to \$750,000 based on current NIEHS funding to be consolidated into the award.

Budget: NIEHS intends to commit \$5M in FY 2019 to fund 4-5 awards. Allowable application budgets are related to the current NIEHS support which will be consolidated into the R35 award. Applicants may request up to \$600,000 in Direct Costs per year. If an individual has NIEHS funding beyond the \$600,000 DC level which will be consolidated given the guidelines above, they may add the additional funds plus 10% to a total of \$750,000 Direct Costs per year. The maximum project period is 8 years.

6. National Institute on Drug Abuse (NIDA) Small Research Grant Program (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-634\)](#)

Type: R03

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIDA Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$50,000 in direct costs per year. The total project period may not exceed two years.

7. Lewy Body Dementia Center Without Walls (CWOW) (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-NS-18-024\)](#)

Type: U54

Application Due Date: April 17, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

Budget: National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) intend to fund an estimate of 1-3 awards, corresponding to a total of \$3,500,000, for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

8. Investigator Initiated Extended Clinical Trial (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-630\)](#)

Type: R01

Application Due Date: April 10, 2018; December 7, 2018; March 7, 2019; December 7, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period of 6 or 7 years.

9. National Institute of Allergy and Infectious Diseases (NIAID) Clinical Trial Implementation Cooperative Agreement (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-633\)](#)

Type: U01

Application Due Date: May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019; September 13, 2019; January 13, 2020; May 13, 2020; September 14, 2020; January 13, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<https://www.niaid.nih.gov/research/role>). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

10. Perception and Cognition Research to Inform Cancer Image Interpretation (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-640\)](#)
[\(PAR-18-641\)](#)

Type: R01
R21

Application Due Date: May 30, 2018; September 26, 2018; May 30, 2019; September 26, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

11. Human-Animal Interaction (HAI) Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-649\)](#)
[\(PAR-18-650\)](#)

Type: R03
R21

Application Due Date: March 30, 2018, March 30, 2019 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites grant applications for research to examine 1) the impact of Human-Animal Interactions (HAI) on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.

Budget: R03 - Direct costs are limited to \$50,000 per year. The maximum project period is two years. R21- Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

12. Opportunities for Collaborative Research at the NIH Clinical Center (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-646\)](#)

Type: *U01*

Application Due Date: April 11, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs). Specifically, the program seeks to broaden and strengthen translational research collaborations between basic and clinical researchers both within and outside NIH to accelerate and enhance translational science by promoting partnerships between NIH intramural investigators (e.g., those conducting research within the labs and clinics of the NIH) and extramural investigators (e.g., those conducting research in labs outside the NIH), and by providing support for extramural investigators to take advantage of the unique research opportunities available at the NIH Clinical Center by conducting research projects in collaboration with NIH intramural investigators. In order to be eligible for this program, the application must include at least one intramural scientist as Program Director/Principal Investigator or collaborator, and at least some of the research must be conducted at the NIH Clinical Center. Through this collaboration, external researchers may gain access to the NIH Clinical Center and leverage the diverse Clinical Center resources, expertise, and infrastructure available to test promising laboratory- and animal-based discoveries with potential for advancing disease diagnosis, treatment and prevention. The special environment of the Clinical Center can support studies that may not be readily supported elsewhere. This may include collaborations that propose targeted increases in new patients enrolled in protocols at the Clinical Center.

Budget: Application budgets need to reflect the actual needs of the proposed project. The maximum amount available per application is \$500,000 direct costs per year; this amount includes extramural grantee costs, Clinical Center costs and intramural investigator's costs attributed to the proposed research project. The total of all three types of cost must not exceed \$500,000 (direct costs) per year. The NIH Clinical Center costs and intramural investigator's costs will not be included in the award paid to the grantee. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).